Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial
and operating results for the fourth quarter and full year ended
December 31, 2023. The Company achieved each of its full-year
guidance metrics for 2023, as highlighted below.
Full-Year Performance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, |
|
|
($ in
millions, except per share amounts) |
|
2023 |
|
2022 |
|
Change (%) |
|
|
|
|
|
|
|
|
Total
revenue |
|
$ |
1,657.7 |
|
|
$ |
1,356.7 |
|
|
22.2 |
% |
Gross profit |
|
$ |
353.8 |
|
|
$ |
302.3 |
|
|
17.0 |
% |
Operating income
(loss) |
|
$ |
20.6 |
|
|
$ |
(19.1 |
) |
|
nm |
Net income
(loss)a |
|
$ |
23.1 |
|
|
$ |
(8.6 |
) |
|
nm |
Non-GAAP adjusted
net incomeb |
|
$ |
81.5 |
|
|
$ |
63.7 |
|
|
27.9 |
% |
Net income (loss)
per share |
|
$ |
0.20 |
|
|
$ |
(0.08 |
) |
|
nm |
Non-GAAP adjusted
net income per share |
|
$ |
0.64 |
|
|
$ |
0.52 |
|
|
23.1 |
% |
|
|
|
|
|
|
|
|
a. |
Net income for full-year 2023 included $37.1 million in non-cash
stock compensation expense and $7.9 million in legal,
non-recurring, and other expenses. Net loss for full-year 2022
included $67.4 million in non-cash stock compensation expense and
$8.0 million in legal, non-recurring, and other expenses. |
b. |
Reconciliations of non-GAAP adjusted net income and other non-GAAP
financial measures are presented in tables near the end of this
press release. |
|
Highlights from 2023 include:
- Record new provider signings with
Implemented Providers increasing 19.4% from year-end 2022;
- Gross provider
retention of 98+%;
- Strong
fee-for-service collections, value-based care performance and new
markets growth offset an approximate $110 million Practice
Collections headwind due to the restructuring of a capitation
contract announced in 1Q’23;
- Three new market
entries – Connecticut, South Carolina and Washington;
- Strong Platform Contribution
performance helped absorb incremental new market entry costs;
and
- Adjusted EBITDA growth of 18.7%
compared to full-year 2022.
Key Operating and Non-GAAP Financial Metrics
|
|
|
|
|
|
|
For the Years Ended December 31, |
|
|
($ in
millions) |
|
2023 |
|
2022 |
|
Change (%) |
|
|
|
|
|
|
|
Implemented Providers |
|
|
4,305 |
|
|
|
3,606 |
|
|
19.4 |
% |
Value-Based Care Attributed
Lives |
|
|
1,120,000 |
|
|
|
856,000 |
|
|
30.8 |
% |
Practice Collections |
|
$ |
2,839.0 |
|
|
$ |
2,424.1 |
|
|
17.1 |
% |
Care Margin |
|
$ |
359.2 |
|
|
$ |
305.6 |
|
|
17.5 |
% |
Platform Contribution |
|
$ |
173.5 |
|
|
$ |
148.5 |
|
|
16.8 |
% |
Adjusted EBITDA |
|
$ |
72.2 |
|
|
$ |
60.9 |
|
|
18.7 |
% |
|
|
|
|
|
|
|
Full-Year 2023 Actual Performance versus Guidance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial FY 2023 Guidancec |
Updated FY 2023 Guidance |
|
FY 2023 |
($ in
millions) |
Low |
|
High |
|
at January 8, 2024 |
|
Actual |
Implemented Providers |
|
4,050 |
|
|
|
4,150 |
|
|
Above High End |
|
|
4,305 |
|
Attributed
Lives |
|
1,050,000 |
|
|
|
1,150,000 |
|
|
Midpoint |
|
|
1,120,000 |
|
Practice
Collections |
$ |
2,700 |
|
|
$ |
2,850 |
|
|
Midpoint |
|
$ |
2,839.0 |
|
GAAP Revenue |
$ |
1,550 |
|
|
$ |
1,650 |
|
|
Mid to High End |
|
$ |
1,657.7 |
|
Care Margin |
$ |
350 |
|
|
$ |
365 |
|
|
Mid to High End |
|
$ |
359.2 |
|
Platform
Contribution |
$ |
160 |
|
|
$ |
168 |
|
|
Above High End |
|
$ |
173.5 |
|
Adjusted
EBITDAd |
$ |
70 |
|
|
$ |
74 |
|
|
Mid to High End |
|
$ |
72.2 |
|
|
|
|
|
|
|
|
|
|
c. |
Management had not reconciled forward-looking non-GAAP measures to
their most directly comparable GAAP measures of Gross Profit and
Net Income. This is because the Company could not have predicted
with reasonable certainty and without unreasonable efforts the
ultimate outcome of certain GAAP components of such reconciliations
due to market-related assumptions not within our control as well as
certain legal or advisory costs, tax costs or other costs that have
arisen. For these reasons, management is unable to assess the
probable significance of the unavailable information, which could
materially impact the amount of the directly comparable GAAP
measures. |
d. |
Reconciliations of non-GAAP adjusted net income and other non-GAAP
financial measures are presented in tables near the end of this
press release. |
|
Fourth Quarter
Performance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
|
($ in
millions, except per share amounts) |
|
2023 |
|
2022 |
|
Change (%) |
|
|
|
|
|
|
|
|
Total
revenue |
|
$ |
440.8 |
|
|
$ |
364.4 |
|
|
21.0 |
% |
Gross profit |
|
$ |
90.0 |
|
|
$ |
79.2 |
|
|
13.6 |
% |
Operating
income |
|
$ |
1.4 |
|
|
$ |
2.2 |
|
|
nm |
Net incomee |
|
$ |
2.8 |
|
|
$ |
17.8 |
|
|
nm |
Non-GAAP adjusted
net incomef |
|
$ |
20.3 |
|
|
$ |
16.1 |
|
|
26.1 |
% |
Net income per
share |
|
$ |
0.02 |
|
|
|
0.14 |
|
|
nm |
Non-GAAP adjusted
net income per share |
|
$ |
0.15 |
|
|
$ |
0.13 |
|
|
15.4 |
% |
|
|
|
|
|
|
|
|
e. |
Net income for the fourth quarter of 2023 included $11.7 million in
non-cash stock compensation expense and $2.4 million in legal and
other expenses. Net income for the fourth quarter of 2022 included
$9.2 million in non-cash stock compensation expense and $1.7
million in legal and other expenses. |
f. |
Reconciliations of non-GAAP adjusted net income and other non-GAAP
financial measures are presented in tables near the end of this
press release. |
|
Key Operating and Non-GAAP Financial Metrics
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
|
($ in
millions) |
|
2023 |
|
2022 |
|
Change (%) |
|
|
|
|
|
|
|
Practice Collections |
|
$ |
756.6 |
|
|
$ |
634.8 |
|
|
19.2 |
% |
Care Margin |
|
$ |
91.5 |
|
|
$ |
80.1 |
|
|
14.2 |
% |
Platform Contribution |
|
$ |
42.3 |
|
|
$ |
39.1 |
|
|
8.2 |
% |
Adjusted EBITDA |
|
$ |
17.3 |
|
|
$ |
14.3 |
|
|
21.1 |
% |
|
|
|
|
|
|
|
Capital Resources and Cash
Flow
The Company's balance sheet at December 31,
2023 included $389.5 million of cash and cash equivalents and no
debt, compared to cash and cash equivalents of $348.0 million and
no debt at December 31, 2022.
Net cash provided by operating activities for the year ended
December 31, 2023 was $80.8 million compared to $47.2 million
in the prior year (+71.2%). Capital expenditures were $0.1 million
for the year ended December 31, 2023, compared to $0.1 million
in the prior year. The Company invested $42.9 million in 2023 on
business acquisitions to enter new states.
2024 Financial and Business
Outlook g h i
Privia Health’s key actions and areas of focus
in 2024 include:
- Increasing density
and scale in existing geographies through organic provider
growth;
- Limiting
downside-risk arrangements in a challenging Medicare Advantage (MA)
market;
- Renegotiating MA capitation
arrangements for more favorable contract structures and margin
contribution expected to reduce capitated practice collections by
approximately $198 million year-over-year due to revenue
recognition rules as 19,900 attributed lives move to
upside/downside risk arrangements;
- Exiting Delaware
ACO (~12,000 attributed lives in the Medicare Shared Savings
Program), effective January 1, 2024;
- Achieving operating
leverage to drive Adjusted EBITDA growth, and converting 80% of
Adjusted EBITDA to Free Cash Flow (defined as net cash provided by
operating activities less purchases of property and equipment);
and
- Continuing to pursue business
development efforts to enter new states and increase overall
addressable market.
The Company’s 2024 operating and financial
guidance is as follows:
|
FY 2023 |
|
FY 2024 Guidanceg |
Y-Y % Change from FY 2023 |
($ in
millions) |
Actual |
|
Low |
|
High |
|
Low |
|
High |
Implemented Providers |
|
4,305 |
|
|
|
4,650 |
|
|
|
4,750 |
|
|
8.0 |
% |
|
10.3 |
% |
Attributed Lives |
|
1,120,000 |
|
|
|
1,150,000 |
|
|
|
1,200,000 |
|
|
2.7 |
% |
|
7.1 |
% |
Practice Collections |
$ |
2,839.0 |
|
|
$ |
2,775 |
|
|
$ |
2,875 |
|
|
(2.3 |
)% |
|
1.3 |
% |
GAAP Revenue |
$ |
1,657.7 |
|
|
$ |
1,600 |
|
|
$ |
1,675 |
|
|
(3.5 |
)% |
|
1.0 |
% |
Care Margin |
$ |
359.2 |
|
|
$ |
388 |
|
|
$ |
400 |
|
|
8.0 |
% |
|
11.4 |
% |
Platform Contribution |
$ |
173.5 |
|
|
$ |
180 |
|
|
$ |
188 |
|
|
3.8 |
% |
|
8.4 |
% |
Adjusted EBITDAh |
$ |
72.2 |
|
|
$ |
85 |
|
|
$ |
90 |
|
|
17.7 |
% |
|
24.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
Practice Collections guidance includes reduction of approximately
$198 million from renegotiated Medicare Advantage capitation
agreements, and assumes minimal year-over-year increase in Shared
Savings accruals
-
Adjusted EBITDA guidance includes approximately $10-12 million in
start-up costs for new geographies announced in last 15 months
-
Capital expenditures are expected to be less than $1 million in
full-year 2024
-
Approximately 80% of Adjusted EBITDA expected to convert to free
cash flow in FY 2024
-
Effective tax rate expected to be approximately 27-28%
g. |
Management has not reconciled forward-looking non-GAAP measures to
their most directly comparable GAAP measures of Gross Profit and
Net Income. This is because the Company cannot predict with
reasonable certainty and without unreasonable efforts the ultimate
outcome of certain GAAP components of such reconciliations due to
market-related assumptions that are not within our control as well
as certain legal or advisory costs, tax costs or other costs that
may arise. For these reasons, management is unable to assess the
probable significance of the unavailable information, which could
materially impact the amount of the future directly comparable GAAP
measures |
h. |
See “Key Metrics and Non-GAAP Financial Measures” for more
information as to how the Company defines and calculates
Implemented Providers, Attributed Lives, Practice Collections, Care
Margin, Platform Contribution and Adjusted EBITDA, and for a
reconciliation of the most comparable GAAP measures to Care Margin,
Platform Contribution, Adjusted EBITDA, Adjusted Net Income and
Adjusted Net Income Per Share. |
|
Certain non-recurring or non-cash and other expenses will be
treated as an add back in the reconciliation of Net Income to
Adjusted EBITDA, and the reconciliation of Net Income to Adjusted
Net Income and Adjusted Net Income Per Share, the details of which
can be found in the Reconciliation schedules near the end of this
and in future quarterly financial press releases. |
i. |
Any slight variations in totals due to rounding. |
|
|
Webcast and Conference Call
Information
The Company will host a conference call on
February 27, 2024, at 8:00 am ET to discuss these results and
management’s outlook for future financial and operational
performance. You can visit
ir.priviahealth.com/news-and-events/events-and-presentations to
listen to the call via live webcast. The webcast will be archived
and available for replay for on-demand listening shortly after the
completion of the call under the same link. If you wish to
participate in the live conference call, then please go to
https://register.vevent.com/register/BI4f3d577f597e4536bc0d4c9f66d273ff
to preregister and obtain your dial-in number and passcode.
This news release and the financial statements
contained herein, and the slide presentation for the webcast, are
also available on the Privia Health Investor Relations website at
ir.priviahealth.com.
About Privia Health
Privia Health™ is a technology-driven, national
physician enablement company that collaborates with medical groups,
health plans, and health systems to optimize physician practices,
improve patient experiences, and reward doctors for delivering
high-value care in both in-person and virtual settings. Our
platform is led by top industry talent and exceptional physician
leadership, and consists of scalable operations and end-to-end,
cloud-based technology that reduces unnecessary healthcare costs,
achieves better outcomes, and improves the health of patients and
the well-being of providers. For more information, visit
priviahealth.com.
Non-GAAP Financial Measures
The Company reports and discusses its operating
results using financial measures consistent with accounting
principles generally accepted in the United States ("GAAP"). From
time to time, in press releases, financial presentations, earnings
conference calls or otherwise, the Company may disclose certain
non-GAAP financial measures. The non-GAAP financial measures
presented in this press release should not be viewed as
alternatives or substitutes for the Company's reported GAAP
results. A reconciliation to the most directly comparable GAAP
financial measure is set forth in the tables that accompany this
release.
The Company believes that the non-GAAP financial
measures presented in this press release are relevant and provide
useful information to the Company's management, investors, and
other interested parties about the Company's operating performance
because the measures allow them to understand and compare the
Company's actual and expected operating results during the prior,
current and future periods in a more consistent manner. The
non-GAAP measures presented in this press release may not be
comparable to similarly titled measures used by other companies.
These non-GAAP financial measures are used in addition to and in
conjunction with results presented in accordance with GAAP and
reflect an additional way of viewing aspects of the Company's
operations that, when viewed with GAAP results and the accompanying
reconciliations to corresponding GAAP financial measures, provides
a more complete understanding of the results of operations and
trends affecting the Company's business. These non-GAAP financial
measures should be considered as a supplement to, and not as a
substitute for, or superior to financial measures calculated in
accordance with GAAP.
Safe Harbor Statement
The financial results in this press release
reflect preliminary, unaudited results, which are not final until
the Company’s Form 10-K is filed with the Securities and Exchange
Commission (“SEC”). This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such statements relate to our
current expectations, projections and assumptions about our
business, the economy and future events or conditions. They do not
relate strictly to historical or current facts. Forward-looking
statements can be identified by words such as “aims,”
“anticipates,” "assumes," “believes,” “estimates,” “expects,”
“forecasts,” “future,” “intends,” “likely,” “may,” “outlook,”
“plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,”
“trends,” “will,” “would,” “could,” “should,” and variations of
such terms and similar expressions and references to guidance,
although some forward-looking statements may be expressed
differently. In particular, these include statements relating to,
among other things, our future actions, business plans, objectives
and prospects; expectations for new health system and other
partnerships, including to enter Ohio; and our future operating or
financial performance and projections, including our full year
guidance for 2024. Factors or events that could cause actual
results to differ may emerge from time to time and are difficult to
predict. Should known or unknown risks or uncertainties
materialize, or should underlying assumptions prove inaccurate,
actual results may differ materially from past results and those
anticipated, estimated or projected. We caution you not to place
undue reliance upon any of these forward-looking statements.
Factors related to these risks and uncertainties
include, but are not limited to: compliance with applicable
healthcare laws and government regulations in the heavily regulated
industry in which the Company operates; the Company’s dependence on
relationships with its medical groups, some of which the Company
does not own; the Company’s growth strategy, which may not prove
viable and the Company may not realize expected results; the
Company’s inability to enter into a definitive agreement for its
partnership in Ohio; difficulties implementing the Company’s
proprietary end-to-end, cloud-based technology solution for Privia
physicians and new medical groups; the high level of competition in
the Company’s industry and the Company’s failure to compete and
innovate; challenges in successfully establishing a presence in new
geographic markets; the Company’s reliance on its electronic
medical record vendor, which the Privia Technology Solution is
integrated and built upon; changes in the payer mix of patients and
potential decreases in the Company’s reimbursement rates as a
result of consolidation among commercial payers; the Company’s use,
disclosure, and other processing of personally identifiable
information, including health information, is subject to the Health
Insurance Portability and Accountability Act of 1996 and other
federal and state privacy and security regulations; and those
factors referenced in Part II, Item 1A, other important factors
discussed under the caption “Risk Factors” in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
Company’s subsequent Quarterly Reports on Form 10-Q. All
information in this press release is as of the date of the release,
and the Company undertakes no duty to update this information
unless required by law.
Contact:Robert BorchertSVP,
Investor & Corporate
CommunicationsIR@priviahealth.com817.783.4841
|
Privia Health Group, Inc.Condensed
Consolidated Statements of
Operations(j)(in thousands,
except share and per share data) |
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
Revenue |
$ |
440,828 |
|
|
$ |
364,424 |
|
|
$ |
1,657,737 |
|
|
$ |
1,356,660 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Provider expense |
|
349,378 |
|
|
|
284,368 |
|
|
|
1,298,573 |
|
|
|
1,051,040 |
|
Cost of platform |
|
52,409 |
|
|
|
43,343 |
|
|
|
197,663 |
|
|
|
170,838 |
|
Sales and marketing |
|
6,249 |
|
|
|
5,173 |
|
|
|
24,732 |
|
|
|
19,741 |
|
General and administrative |
|
29,600 |
|
|
|
28,156 |
|
|
|
109,587 |
|
|
|
129,592 |
|
Depreciation and amortization |
|
1,772 |
|
|
|
1,135 |
|
|
|
6,533 |
|
|
|
4,571 |
|
Total operating expenses |
|
439,408 |
|
|
|
362,175 |
|
|
|
1,637,088 |
|
|
|
1,375,782 |
|
Operating income (loss) |
|
1,420 |
|
|
|
2,249 |
|
|
|
20,649 |
|
|
|
(19,122 |
) |
Interest (income) expense,
net |
|
(2,848 |
) |
|
|
(1,152 |
) |
|
|
(8,372 |
) |
|
|
(542 |
) |
Income (loss) before provision
for (benefit from) income taxes |
|
4,268 |
|
|
|
3,401 |
|
|
|
29,021 |
|
|
|
(18,580 |
) |
Provision for (benefit from)
income taxes |
|
1,944 |
|
|
|
(13,447 |
) |
|
|
7,993 |
|
|
|
(6,516 |
) |
Net income (loss) |
|
2,324 |
|
|
|
16,848 |
|
|
|
21,028 |
|
|
|
(12,064 |
) |
Less: Loss attributable to
non-controlling interests |
|
(514 |
) |
|
|
(928 |
) |
|
|
(2,051 |
) |
|
|
(3,479 |
) |
Net income (loss) income
attributable to Privia Health Group, Inc. |
$ |
2,838 |
|
|
$ |
17,776 |
|
|
$ |
23,079 |
|
|
$ |
(8,585 |
) |
Net income (loss) income per
share attributable to Privia Health Group, Inc. stockholders –
basic |
$ |
0.02 |
|
|
$ |
0.16 |
|
|
$ |
0.20 |
|
|
$ |
(0.08 |
) |
Net income (loss) income per
share attributable to Privia Health Group, Inc. stockholders –
diluted |
$ |
0.02 |
|
|
$ |
0.14 |
|
|
$ |
0.19 |
|
|
$ |
(0.08 |
) |
Weighted average common shares
outstanding – basic |
|
118,109,663 |
|
|
|
114,364,180 |
|
|
|
116,731,406 |
|
|
|
110,695,266 |
|
Weighted average common shares
outstanding – diluted |
|
124,831,553 |
|
|
|
124,142,657 |
|
|
|
124,686,067 |
|
|
|
110,695,266 |
|
(j) Any slight variations in totals due to rounding.
|
Privia Health Group, Inc.Condensed
Consolidated Balance Sheets(k)(in
thousands) |
|
|
|
|
|
December 31, 2023 |
|
December 31, 2022 |
Assets |
(unaudited) |
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
389,511 |
|
|
$ |
347,992 |
|
Accounts receivable |
|
290,768 |
|
|
|
189,604 |
|
Prepaid expenses and other current assets |
|
20,525 |
|
|
|
14,366 |
|
Total current assets |
|
700,804 |
|
|
|
551,962 |
|
Non-current assets: |
|
|
|
Property and equipment, net |
|
2,325 |
|
|
|
3,386 |
|
Right-of-use asset |
|
6,612 |
|
|
|
8,089 |
|
Intangible assets, net |
|
107,630 |
|
|
|
57,387 |
|
Goodwill |
|
138,749 |
|
|
|
126,938 |
|
Deferred tax asset |
|
35,200 |
|
|
|
40,368 |
|
Other non-current assets |
|
8,580 |
|
|
|
4,683 |
|
Total non-current assets |
|
299,096 |
|
|
|
240,851 |
|
Total assets |
$ |
999,900 |
|
|
$ |
792,813 |
|
|
|
|
|
Liabilities and
stockholders’ equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable and accrued expenses |
$ |
57,831 |
|
|
$ |
52,837 |
|
Provider liability |
|
326,078 |
|
|
|
208,424 |
|
Operating lease liabilities, current |
|
3,043 |
|
|
|
3,013 |
|
Total current liabilities |
|
386,952 |
|
|
|
264,274 |
|
Non-current liabilities: |
|
|
|
Operating lease liabilities, non-current |
|
5,246 |
|
|
|
8,490 |
|
Other non-current liabilities |
|
313 |
|
|
|
1,000 |
|
Total non-current
liabilities |
|
5,559 |
|
|
|
9,490 |
|
Total liabilities |
|
392,511 |
|
|
|
273,764 |
|
Commitments and
contingencies |
|
|
|
Stockholders’ equity: |
|
|
|
Common stock |
|
1,182 |
|
|
|
1,148 |
|
Additional paid-in capital |
|
753,869 |
|
|
|
714,639 |
|
Accumulated deficit |
|
(193,614 |
) |
|
|
(216,693 |
) |
Total Privia Health Group, Inc. stockholders’ equity |
|
561,437 |
|
|
|
499,094 |
|
Non-controlling interest |
|
45,952 |
|
|
|
19,955 |
|
Total stockholders’
equity |
|
607,389 |
|
|
|
519,049 |
|
Total liabilities and
stockholders’ equity |
$ |
999,900 |
|
|
$ |
792,813 |
|
(k) Any slight variations in totals are due to rounding.
|
Privia Health Group, Inc.Condensed
Consolidated Statements of Cash
Flows(l)(in
thousands) |
|
|
|
For the Years Ended December 31, |
|
2023 |
|
2022 |
|
(unaudited) |
|
|
Cash flows from operating activities |
|
|
|
Net income (loss) |
$ |
21,028 |
|
|
$ |
(12,064 |
) |
Adjustments to reconcile loss
to net cash provided by operating activities: |
|
|
|
Depreciation |
|
1,174 |
|
|
|
1,220 |
|
Amortization of intangibles |
|
5,359 |
|
|
|
3,351 |
|
Amortization of debt issuance costs |
|
— |
|
|
|
687 |
|
Stock-based compensation |
|
37,098 |
|
|
|
67,359 |
|
Deferred tax expense (benefit) |
|
7,465 |
|
|
|
(7,004 |
) |
Changes in asset and
liabilities: |
|
|
|
Accounts receivable |
|
(96,877 |
) |
|
|
(72,202 |
) |
Prepaid expenses and other current assets |
|
(6,159 |
) |
|
|
(5,669 |
) |
Other non-current assets and right-of-use asset |
|
(2,418 |
) |
|
|
1,383 |
|
Accounts payable and accrued expenses |
|
4,994 |
|
|
|
6,852 |
|
Provider liability |
|
113,367 |
|
|
|
67,716 |
|
Operating lease liabilities |
|
(3,214 |
) |
|
|
(2,433 |
) |
Other long-term liabilities |
|
(1,032 |
) |
|
|
(2,000 |
) |
Net cash provided by operating
activities |
|
80,785 |
|
|
|
47,196 |
|
Cash flows from investing
activities |
|
|
|
Purchases of property and equipment |
|
(113 |
) |
|
|
(104 |
) |
Business acquisitions, net of cash acquired |
|
(42,858 |
) |
|
|
— |
|
Net cash used in investing
activities |
|
(42,971 |
) |
|
|
(104 |
) |
Cash flows from financing
activities |
|
|
|
Repurchase of non-controlling interest |
|
(5,694 |
) |
|
|
— |
|
Proceeds from non-controlling interest |
|
659 |
|
|
|
125 |
|
Repayment of note payable |
|
— |
|
|
|
(33,250 |
) |
Proceeds from exercised stock options |
|
8,740 |
|
|
|
13,448 |
|
Net cash provided by (used in)
financing activities |
|
3,705 |
|
|
|
(19,677 |
) |
Net increase in cash and cash
equivalents |
|
41,519 |
|
|
|
27,415 |
|
Cash and cash equivalents at
beginning of period |
|
347,992 |
|
|
|
320,577 |
|
Cash and cash equivalents at
end of period |
$ |
389,511 |
|
|
$ |
347,992 |
|
|
|
|
|
Supplemental disclosure of
cash flow information: |
|
|
|
Interest paid |
$ |
40 |
|
|
$ |
713 |
|
Income taxes paid |
$ |
1,040 |
|
|
$ |
307 |
|
(l) Any slight variations in totals are due to rounding.
Additional Financial Information
Revenues disaggregated by source:
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(Dollars in Thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
FFS-patient care |
$ |
272,343 |
|
|
$ |
231,624 |
|
|
$ |
976,688 |
|
|
$ |
869,165 |
|
FFS-administrative
services |
|
29,741 |
|
|
|
23,018 |
|
|
|
113,154 |
|
|
|
94,929 |
|
Capitated revenue |
|
85,248 |
|
|
|
57,687 |
|
|
|
338,729 |
|
|
|
218,463 |
|
Shared savings |
|
39,838 |
|
|
|
42,319 |
|
|
|
170,143 |
|
|
|
132,615 |
|
Care management fees
(PMPM) |
|
10,615 |
|
|
|
8,023 |
|
|
|
50,519 |
|
|
|
35,541 |
|
Other revenue |
|
3,043 |
|
|
|
1,754 |
|
|
|
8,504 |
|
|
|
5,947 |
|
Total Revenue |
$ |
440,828 |
|
|
$ |
364,425 |
|
|
$ |
1,657,737 |
|
|
$ |
1,356,660 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company’s liabilities for unpaid medical claims
under at-risk capitation arrangements:
|
|
|
|
|
December 31, |
(Dollars in Thousands) |
|
2023 |
|
2022 |
Balance, beginning of period |
|
$ |
28,617 |
|
|
$ |
— |
|
Incurred health care costs |
|
|
|
|
Current year |
|
|
334,383 |
|
|
|
218,199 |
|
Prior years |
|
|
2,436 |
|
|
|
— |
|
Total claims incurred |
|
$ |
336,819 |
|
|
$ |
218,199 |
|
Claims Paid |
|
|
|
|
Current year |
|
$ |
(270,810 |
) |
|
$ |
(189,582 |
) |
Prior years |
|
|
(27,488 |
) |
|
|
— |
|
Total claims paid |
|
$ |
(298,298 |
) |
|
$ |
(189,582 |
) |
Balance, end of period |
|
$ |
67,138 |
|
|
$ |
28,617 |
|
|
|
|
|
|
|
|
|
|
Key Metrics and Non-GAAP Financial Measures
Privia Health reviews a number of operating and
financial metrics, including the following key metrics and non-GAAP
financial measures, to evaluate the Company’s business, measure
performance, identify trends affecting the Company’s business,
formulate business plans, and make strategic decisions.
Key
Metrics(m)
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited; $ in
millions) |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
|
|
|
|
|
|
|
|
Implemented Providers(n) |
|
|
4,305 |
|
|
|
3,606 |
|
|
|
4,305 |
|
|
|
3,606 |
|
Attributed Lives(o) |
|
|
1,120,000 |
|
|
|
856,000 |
|
|
|
1,120,000 |
|
|
|
856,000 |
|
Practice Collections(p) |
|
$ |
756.6 |
|
|
$ |
634.8 |
|
|
$ |
2,839.0 |
|
|
$ |
2,424.1 |
|
|
|
|
|
|
|
|
|
|
(m)Any slight
variations in totals are due to rounding. |
(n)Implemented
Providers is defined as the total of all service professionals on
Privia Health’s platform at the end of a given period who are
credentialed by Privia Health and billed for medical services, in
both Owned and Non-Owned Medical Groups during that period. |
(o)Attributed
Lives are defined as any patient that a payer deems attributed to
Privia to deliver care as part of a value-based care arrangement
through a provider of primary care services as of the end of a
particular period. |
(p)Practice
Collections are defined as the total collections from all practices
in all markets and all sources of reimbursement that the Company
receives for delivering care and providing Privia Health’s platform
and associated services. Practice Collections differ from revenue
by including collections from Non-Owned Medical Groups. |
|
Non-GAAP Financial Measures
(q)(r)
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited; $ in
thousands) |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
|
|
|
|
|
|
|
|
Care Margin |
|
$ |
91,450 |
|
|
$ |
80,056 |
|
|
$ |
359,164 |
|
|
$ |
305,620 |
|
Platform Contribution |
|
$ |
42,282 |
|
|
$ |
39,089 |
|
|
$ |
173,481 |
|
|
$ |
148,540 |
|
Platform Contribution
Margin |
|
|
46.2 |
% |
|
|
48.8 |
% |
|
|
48.3 |
% |
|
|
48.6 |
% |
Adjusted EBITDA |
|
$ |
17,279 |
|
|
$ |
14,265 |
|
|
$ |
72,228 |
|
|
$ |
60,852 |
|
Adjusted EBITDA Margin |
|
|
18.9 |
% |
|
|
17.8 |
% |
|
|
20.1 |
% |
|
|
19.9 |
% |
|
|
|
|
|
|
|
|
|
(q)In addition to
results reported in accordance with GAAP, Privia Health discloses
Care Margin, Platform Contribution, Platform Contribution margin,
Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP
financial measures. Each are defined as follows:
- Care Margin is Gross Profit excluding amortization of
intangible assets.
- Platform Contribution is Gross Profit, excluding amortization
of intangible assets, less Cost of platform and excluding
stock-based compensation expense included in Cost of platform.
- Platform Contribution margin is Platform Contribution divided
by Care Margin.
- Adjusted EBITDA is net income (loss) attributable to Privia
Health Group, Inc. shareholders and subsidiaries excluding
non-controlling interests, provision for (benefit from) income
taxes, interest income, interest expense, depreciation and
amortization, stock-based compensation, employer taxes on equity
vesting/exercises, severance charges and other nonrecurring
expenses.
- Adjusted EBITDA Margin is Adjusted EBITDA divided by Care
Margin.
|
(r)Any slight
variations in totals are due to rounding. |
|
Reconciliation of Gross Profit to Care
Margin(s)
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited; $ in
thousands) |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Revenue |
|
$ |
440,828 |
|
|
$ |
364,424 |
|
|
$ |
1,657,737 |
|
|
$ |
1,356,660 |
|
Provider expense |
|
|
(349,378 |
) |
|
|
(284,368 |
) |
|
|
(1,298,573 |
) |
|
|
(1,051,040 |
) |
Amortization of intangible
assets |
|
|
(1,477 |
) |
|
|
(842 |
) |
|
|
(5,359 |
) |
|
|
(3,351 |
) |
Gross Profit |
|
$ |
89,973 |
|
|
$ |
79,214 |
|
|
$ |
353,805 |
|
|
$ |
302,269 |
|
Amortization of intangible
assets |
|
|
1,477 |
|
|
|
842 |
|
|
|
5,359 |
|
|
|
3,351 |
|
Care margin |
|
$ |
91,450 |
|
|
$ |
80,056 |
|
|
$ |
359,164 |
|
|
$ |
305,620 |
|
(s)Any slight
variations in totals are due to rounding. |
|
Reconciliation of Gross Profit to
Platform
Contribution(t)
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited; $ in
thousands) |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Revenue |
|
$ |
440,828 |
|
|
$ |
364,424 |
|
|
$ |
1,657,737 |
|
|
$ |
1,356,660 |
|
Provider expense |
|
|
(349,378 |
) |
|
|
(284,368 |
) |
|
|
(1,298,573 |
) |
|
|
(1,051,040 |
) |
Amortization of intangible
assets |
|
|
(1,477 |
) |
|
|
(842 |
) |
|
|
(5,359 |
) |
|
|
(3,351 |
) |
Gross Profit |
|
|
89,973 |
|
|
|
79,214 |
|
|
|
353,805 |
|
|
|
302,269 |
|
Amortization of intangible
assets |
|
|
1,477 |
|
|
|
842 |
|
|
|
5,359 |
|
|
|
3,351 |
|
Cost of platform |
|
|
(52,409 |
) |
|
|
(43,343 |
) |
|
|
(197,663 |
) |
|
|
(170,838 |
) |
Stock-based
compensation(u) |
|
|
3,241 |
|
|
|
2,376 |
|
|
|
11,980 |
|
|
|
13,758 |
|
Platform Contribution |
|
$ |
42,282 |
|
|
$ |
39,089 |
|
|
$ |
173,481 |
|
|
$ |
148,540 |
|
(t)Any slight
variations in totals are due to rounding. |
(u)Amount
represents stock-based compensation expense included under Cost of
Platform. |
|
Reconciliation of Net Income (Loss) to Adjusted
EBITDA(v)
|
|
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited;
$ in thousands) |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Net income (loss) |
|
$ |
2,838 |
|
|
$ |
17,776 |
|
|
$ |
23,079 |
|
|
$ |
(8,585 |
) |
Net (loss) attributable to
non-controlling interests |
|
|
(514 |
) |
|
|
(928 |
) |
|
|
(2,051 |
) |
|
|
(3,479 |
) |
Provision for (benefit from)
income taxes |
|
|
1,944 |
|
|
|
(13,447 |
) |
|
|
7,993 |
|
|
|
(6,516 |
) |
Interest expense |
|
|
(2,848 |
) |
|
|
(1,152 |
) |
|
|
(8,372 |
) |
|
|
(542 |
) |
Depreciation and
amortization |
|
|
1,772 |
|
|
|
1,135 |
|
|
|
6,533 |
|
|
|
4,571 |
|
Stock-based compensation |
|
|
11,669 |
|
|
|
9,175 |
|
|
|
37,098 |
|
|
|
67,359 |
|
Other expenses(w) |
|
|
2,418 |
|
|
|
1,706 |
|
|
|
7,948 |
|
|
|
8,044 |
|
Adjusted EBITDA |
|
$ |
17,279 |
|
|
$ |
14,265 |
|
|
$ |
72,228 |
|
|
$ |
60,852 |
|
|
|
|
|
|
|
|
|
|
(v)Any slight variations in totals are due to rounding. |
(w)Other expenses include employer taxes on equity
vesting/exercises, legal, severance and certain non-recurring
costs. Employer taxes on equity vesting/exercises of $1.6 million
and $3.2 million were recorded for the years ended
December 31, 2023 and 2022, respectively. |
|
Reconciliation of Net Income (Loss) to Adjusted Net
Income and Adjusted Net Income Per
Share(x)
|
|
|
|
|
For the Three Months Ended December 31, |
|
For the Years Ended December 31, |
(unaudited;
$ in thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
Net income (loss) |
$ |
2,838 |
|
|
$ |
17,776 |
|
|
$ |
23,079 |
|
|
$ |
(8,585 |
) |
Stock-based compensation |
|
11,669 |
|
|
|
9,175 |
|
|
|
37,098 |
|
|
|
67,359 |
|
Intangible amortization
expense |
|
1,477 |
|
|
|
842 |
|
|
|
5,359 |
|
|
|
3,351 |
|
Provision for (benefit from)
income tax |
|
1,944 |
|
|
|
(13,447 |
) |
|
|
7,993 |
|
|
|
(6,516 |
) |
Other expenses(y) |
|
2,418 |
|
|
|
1,706 |
|
|
|
7,948 |
|
|
|
8,044 |
|
Adjusted net income
attributable to Privia Health Group, Inc. |
$ |
20,346 |
|
|
$ |
16,052 |
|
|
$ |
81,477 |
|
|
$ |
63,653 |
|
Adjusted net income per share
attributable to Privia Health Group, Inc. stockholders – basic |
$ |
0.16 |
|
|
$ |
0.14 |
|
|
$ |
0.69 |
|
|
$ |
0.58 |
|
Adjusted net income per share
attributable to Privia Health Group, Inc. stockholders –
diluted |
$ |
0.15 |
|
|
$ |
0.13 |
|
|
$ |
0.64 |
|
|
$ |
0.52 |
|
Weighted average common shares
outstanding – basic |
|
118,109,663 |
|
|
|
114,364,180 |
|
|
|
116,731,406 |
|
|
|
110,695,266 |
|
Weighted average common shares
outstanding – diluted |
|
124,924,442 |
|
|
|
124,142,657 |
|
|
|
125,084,821 |
|
|
|
122,952,853 |
|
(x)Any slight
variations in totals due to rounding. |
(y)Other expenses include employer taxes on equity
vesting/exercises, legal, severance and certain non-recurring
costs. Employer taxes on equity vesting/exercises of $1.6 million
and $3.2 million were recorded for the years ended
December 31, 2023 and 2022, respectively. |
|
Privia Health (NASDAQ:PRVA)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Privia Health (NASDAQ:PRVA)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024